Literature DB >> 3249703

Autoimmunity in chronic lymphocytic leukaemia.

M Lischner1, M Prokocimer, A Zolberg, M Shaklai.   

Abstract

Seventy-nine patients with chronic lymphocytic leukaemia were evaluated for the presence of autoimmune diseases and autoantibodies. One patient has polymyositis and two additional patients presented with features suggestive of pernicious anaemia and chronic active hepatitis. The Coombs' direct test was positive in 7% and immune thrombocytopenia was present in 8.1% of patients. Five (7%) patients had M-protein in the serum. No increased frequency of other autoantibodies was noted in our study group. We conclude that the propensity to develop antibodies is restricted only to the haematopoietic system and that there is no increased frequency of non-haematological autoimmune diseases in chronic lymphatic leukaemia.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3249703      PMCID: PMC2428921          DOI: 10.1136/pgmj.64.754.590

Source DB:  PubMed          Journal:  Postgrad Med J        ISSN: 0032-5473            Impact factor:   2.401


  11 in total

1.  Idiopathic thrombocytopenic purpura complicating chronic lymphocytic leukemia.

Authors:  R W Carey; A McGinnis; B M Jacobson; A Carvalho
Journal:  Arch Intern Med       Date:  1976-01

2.  Pure red blood cell aplasia and chronic lymphocytic leukemia.

Authors:  M D Abeloff; L Waterbury
Journal:  Arch Intern Med       Date:  1974-10

3.  Cold urticaria with cryoglobulinemia in a patient with chronic lymphocytic leukemia.

Authors:  H M Rawnsley; W B Shelley
Journal:  Arch Dermatol       Date:  1968-07

Review 4.  Chronic lymphocytic leukemia. Recent advances in biology and treatment.

Authors:  R P Gale; K A Foon
Journal:  Ann Intern Med       Date:  1985-07       Impact factor: 25.391

5.  Increase in T gamma lymphocytes in B-cell chronic lymphocytic leukaemia. II. Correlation with clinical stage and findings in B-prolymphocytic leukaemia.

Authors:  D Catovsky; F Lauria; E Matutes; R Foa; V Mantovani; S Tura; D A Galton
Journal:  Br J Haematol       Date:  1981-04       Impact factor: 6.998

6.  Abnormal T-cell subpopulation function in CLL: excessive suppressor (T gamma) and deficient helper (T mu) activity with respect to B-cell proliferation.

Authors:  N E Kay
Journal:  Blood       Date:  1981-03       Impact factor: 22.113

7.  Peripheral destruction of platelets in chronic lymphocytic leukemia: recognition, prognosis and therapeutic implications.

Authors:  D B Rubinstein; D L Longo
Journal:  Am J Med       Date:  1981-10       Impact factor: 4.965

8.  X-radiation and alkylating agents as possible "trigger" mechanisms in the autoimmune complications of malignant lymphophroliferative disease.

Authors:  F B Lewis; R S Schwartz; W Dameshek
Journal:  Clin Exp Immunol       Date:  1966-01       Impact factor: 4.330

9.  Autoimmune hyperthyroidism and thrombocytopenia developing in a patient with chronic lymphocytic leukemia.

Authors:  A Haubenstock; R Zalusky
Journal:  Am J Hematol       Date:  1985-07       Impact factor: 10.047

Review 10.  The chronic leukemias: a review of disease manifestations and the aims of therapy.

Authors:  D E Bergsagel
Journal:  Can Med Assoc J       Date:  1967-06-24       Impact factor: 8.262

View more
  4 in total

1.  Systemic sclerosis and chronic lymphocytic leukaemia.

Authors:  Y Sidi; R Fadilah; J Pinkhas; M Prokocimer
Journal:  Postgrad Med J       Date:  1990-12       Impact factor: 2.401

2.  Anti-globulin test positivity indicates advanced disease in Indian CLL patients.

Authors:  Richa Gupta; Neha Garg; Abha Singh
Journal:  Am J Blood Res       Date:  2021-04-15

3.  Treatment of Hypersplenism by Partial Splenic Embolization Through Gastric Collaterals.

Authors:  Souheil Saddekni; Amr Soliman Moustafa; Hany A Tahoon; Mostafa Setita; Ahmed Kamel Abdel-Aal
Journal:  J Radiol Case Rep       Date:  2016-03-31

4.  Polymyositis associated with chronic myelogenous leukemia.

Authors:  L C Pagliaro; P Mancias
Journal:  Ann Hematol       Date:  1994-04       Impact factor: 3.673

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.